Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Lunit, Seoul, South Korea.
Head Neck. 2023 Dec;45(12):3086-3095. doi: 10.1002/hed.27537. Epub 2023 Oct 13.
This study analyzed the predictive value of artificial intelligence (AI)-powered tumor-infiltrating lymphocyte (TIL) analysis in recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) treated with axitinib.
Patients from a multicenter, prospective phase II trial evaluating axitinib efficacy in R/M ACC were included in this study. H&E whole-side images of archival tumor tissues were analyzed by Lunit SCOPE IO, an AI-powered spatial TIL analyzer.
Twenty-seven patients were included in the analysis. The best response was stable disease, and the median progression-free survival (PFS) was 11.1 months (95% CI, 9.2-13.7 months). Median TIL densities in the cancer and surrounding stroma were 25.8/mm (IQR, 8.3-73.0) and 180.4/mm (IQR, 69.6-342.8), respectively. Patients with stromal TIL density >342.5/mm exhibited longer PFS (p = 0.012).
Cancer and stromal area TIL infiltration were generally low in R/M ACC. Higher stromal TIL infiltration was associated with a longer PFS with axitinib treatment.
本研究分析了人工智能（AI）驱动的肿瘤浸润淋巴细胞（TIL）分析在接受阿昔替尼治疗的复发性或转移性（R/M）腺样囊性癌（ACC）中的预测价值。
本研究纳入了一项多中心、前瞻性评估阿昔替尼治疗 R/M ACC 疗效的 II 期临床试验中的患者。采用人工智能驱动的空间 TIL 分析工具 Lunit SCOPE IO 对存档肿瘤组织的 H&E 全切片图像进行分析。
共纳入 27 例患者进行分析。最佳缓解为疾病稳定，中位无进展生存期（PFS）为 11.1 个月（95%CI，9.2-13.7 个月）。肿瘤和周围基质中 TIL 密度的中位数分别为 25.8/mm（IQR，8.3-73.0）和 180.4/mm（IQR，69.6-342.8）。基质中 TIL 密度＞342.5/mm 的患者 PFS 更长（p=0.012）。
R/M ACC 中的肿瘤和基质区 TIL 浸润通常较低。较高的基质 TIL 浸润与阿昔替尼治疗后更长的 PFS 相关。
